Literature DB >> 15766555

C-reactive protein binds to the 3beta-OH group of cholesterol in LDL particles.

Sanna Taskinen1, Marja Hyvönen, Petri T Kovanen, Seppo Meri, Markku O Pentikäinen.   

Abstract

C-reactive protein (CRP) has been suggested to contribute to the development of atherosclerosis. We previously found binding of CRP to cholesterol in modified low density lipoprotein (LDL) particles. Here, we characterize the interaction between CRP and cholesterol in more detail. When lipids of native LDL were separated by thin-layer chromatography, CRP bound only to cholesterol. When various cholesterol analogues were compared for their ability to bind CRP, we found that any modification of the 3beta-OH group blocked binding of CRP to cholesterol. Similarly, enrichment of LDL with cholesterol but not with its analogues triggered the binding of CRP to LDL. Finally, with the aid of anti-CRP monoclonal antibodies and by molecular modeling, we obtained evidence for involvement of the phosphorylcholine-binding site of CRP in cholesterol binding. Thus, CRP can bind to cholesterol, and the interaction is mediated by the phosphorylcholine-binding site of CRP and the 3beta-hydroxyl group of cholesterol.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15766555     DOI: 10.1016/j.bbrc.2005.02.091

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

1.  C-reactive protein and atherogenesis: new insights from established animal models.

Authors:  Jan Torzewski
Journal:  Am J Pathol       Date:  2005-10       Impact factor: 4.307

2.  Associations between abnormal rod-mediated dark adaptation and health and functioning in older adults with normal macular health.

Authors:  Cynthia Owsley; Carrie Huisingh; Gregory R Jackson; Christine A Curcio; Alexander J Szalai; Nassrin Dashti; Mark Clark; Kia Rookard; Mark A McCrory; Tyler T Wright; Michael A Callahan; Lanning B Kline; C Douglas Witherspoon; Gerald McGwin
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-22       Impact factor: 4.799

3.  Atherosclerosis-related functions of C-reactive protein.

Authors:  Alok Agrawal; David J Hammond; Sanjay K Singh
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2010-12-01

4.  Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein.

Authors:  Matti Laine; Hanna Jarva; Sanna Seitsonen; Karita Haapasalo; Markus J Lehtinen; Nina Lindeman; Don H Anderson; Patrick T Johnson; Irma Järvelä; T Sakari Jokiranta; Gregory S Hageman; Ilkka Immonen; Seppo Meri
Journal:  J Immunol       Date:  2007-03-15       Impact factor: 5.422

Review 5.  Regulation of Conformational Changes in C-reactive Protein Alters its Bioactivity.

Authors:  Naeem Ullah; Yi Wu
Journal:  Cell Biochem Biophys       Date:  2022-08-23       Impact factor: 2.989

Review 6.  The connection between C-reactive protein and atherosclerosis.

Authors:  Sanjay K Singh; Madathilparambil V Suresh; Bhavya Voleti; Alok Agrawal
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

7.  Therapeutic potential of phosphoethanolamine-bound C-reactive protein in atherosclerosis.

Authors:  Alok Agrawal
Journal:  Future Lipidol       Date:  2008-12

Review 8.  Pentraxins, anti-pentraxin antibodies, and atherosclerosis.

Authors:  N Bassi; S Zampieri; A Ghirardello; M Tonon; M Zen; F Cozzi; A Doria
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

9.  C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells.

Authors:  Sanjay K Singh; Madathilparambil V Suresh; Deborah C Prayther; Jonathan P Moorman; Antonio E Rusiñol; Alok Agrawal
Journal:  J Immunol       Date:  2008-03-15       Impact factor: 5.422

Review 10.  C-reactive protein in human atherogenesis: facts and fiction.

Authors:  Oliver Zimmermann; Kefei Li; Myron Zaczkiewicz; Matthias Graf; Zhongmin Liu; Jan Torzewski
Journal:  Mediators Inflamm       Date:  2014-04-01       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.